Taisho Pharma Co

Taisho Pharma Co., a research and development services company based in Japan, reported a total of approximately 50.09 billion kg CO2e in emissions for the fiscal year ending March 31, 2021. This figure encompasses Scope 1 and Scope 2 emissions, which collectively amounted to around 50.09 billion kg CO2e.

Scope 1 emissions for the same period were approximately 22.35 billion kg CO2e, while Scope 2 emissions were approximately 27.73 billion kg CO2e. The company also disclosed Scope 3 emissions, with significant contributions from purchased goods and services (about 81.26 billion kg CO2e), capital goods (about 47.76 billion kg CO2e), and fuel and energy-related activities (about 4.21 billion kg CO2e).

In the fiscal year ending March 31, 2020, Taisho Pharma Co. reported total emissions of approximately 51.89 billion kg CO2e, comprising Scope 1 emissions of about 22.95 billion kg CO2e and Scope 2 emissions of about 28.94 billion kg CO2e. Scope 3 emissions in 2020 included purchased goods and services at approximately 89.00 billion kg CO2e and capital goods at about 42.79 billion kg CO2e.

Taisho Pharma Co. has set a long-term climate commitment to reduce its Scope 1 and Scope 2 CO2 emissions by 46% by the fiscal year ending March 31, 2031, using the fiscal year ended March 31, 2014, as a baseline. The company is recognised as a current subsidiary of Taisho Pharmaceutical Co., Ltd., and its CDP data originates from Taisho Pharmaceutical Holdings Co., Ltd. at cascade level 1.